Mbappe health update after Real Madrid star taken to hospital

Kylian Mbappe has been discharged from a hospital in the United States after being admitted for an acute case of gastroenteritis and a fever.
The 26-year-old France international missed Real Madrid 's 1-1 Club World Cup draw with Al Hilal due to his illness.
Real Madrid confirmed Mbappe's return to the team's training base to continue his recovery.
He will continue to receive specific medical treatment and is expected to gradually return to team activity.
Real Madrid is scheduled to play their second Group H fixture against Mexican side CF Pachuca on Sunday.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mail​

9 minutes ago

• Daily Mail​

Vikings' Justin Jefferson caught playing Fortnite at Pacers-Thunder game after Stephen A's solitaire uproar

Minnesota Vikings star Justin Jefferson didn't let front-row seats at the NBA Finals stop him from gaming on Thursday night in Indianapolis. A viral clip from the Indiana Pacers' Game 6 win over the Oklahoma City Thunder shows Jefferson playing ' Fortnite ' on his mobile device as a seatmate thumbs around on his phone. Many fans were outraged to see two people squandering courtside seats along the baseline, which were valued at around $50,000 on the resale market. 'Imagine being rich enough where 10 to 50 thousand dollar tickets don't even matter,' one critic wrote in response to the social media clip. Many others offered some version of: 'Just watch the game.' Of course, the clip appears to come from before the opening tip. And while most NBA fans would feel lucky to watch warmups from the baseline, Jefferson is no stranger to that vantagepoint. The former LSU star is a near-fixture at Minnesota Timberwolves games and was regularly seen sitting courtside throughout the playoffs. A clip from the Indiana Pacers' Game 6 win over the Oklahoma City Thunder shows Jefferson (left) playing ' Fortnite ' on his mobile device as a seatmate thumbs around on his phone The viral clip does serve as another warning for high-profile NBA playoff attendees. Just last week, ESPN's Stephen A. Smith was caught playing solitaire during Game 4 of the Finals. A clip of the distracted sports media personality subsequently went viral, leading Smith to offer a defense online. 'Yep! That's me,' Smith wrote. 'Who would've thought….I can multi-task. Especially during TIMEOUTS! Hope y'all are enjoying the NBA Finals. This is going 7 games now, peeps!' Smith was right about this series going seven games. Oklahoma City entered Thursday with a chance to eliminate Indiana on the Pacers' homecourt, but instead fell 108-91. Now the Thunder will have homecourt advantage for the 2024-25 season finale on Sunday night. Once again, the Pacers bench outshined the Thunder's, as power forward Obi Toppin had a team-high 20 points. Meanwhile, Oklahoma City sixth man Alex Caruso had a -33 plus-minus rating for the game as he failed to score. Jefferson and his Vikings teammates are now done with organized team activities (OTAs) and minicamp. They'll return to the team facility in Eagan, Minnesota when training camp begins on July 26.

Metro

11 minutes ago

• Metro

Chelsea sent warning over £43m Man Utd and Liverpool transfer target

Chelsea have been warned they will be making a mistake if they peruse the signing of Manchester United and Liverpool traget Malick Fofana. The Lyon youngster is in high-demand after an eye-catching campaign for the Ligue 1 club who have already sold Rayan Cherki to Manchester City this summer. Fofana is likely to command a fee in the region of £43million for a player they signed from Gent in January 2024 for just £17m. Ex-Chelsea defender William Gallas, however, believes Fofana should not be a player Chelsea are focusing on buying this summer, even if rival clubs could benefit from his talent. 'Malick Fofana is a young player that is still learning and I don't think that is the right move,' Gallas told Prime Casino. Wake up to find news on your club in your inbox every morning with Metro's Football Newsletter. Sign up to our newsletter and then select your team in the link we'll send you so we can get football news tailored to you. 'Chelsea have a lot of forward players already and I think they need experienced defenders now. They have won the Conference League but that right centre-back position is the one I'd look at, not wingers.' The Blues are currently involved in Club World Cup action in America and it remains to be seen what impact that tournament will have on their preparations ahead of the new Premier League season. Chelsea appear to have been handed a kind start to the season after the fixtures were announced earlier this week, but Gallas is concerned games against the likes of Crystal Palace and Brighton will be far tougher in reality than on paper. He added: 'Chelsea will want to get off to a good start as they look to go and finish in the top four and be in the race to win the title, but they've got a difficult start. Sun Aug 17 – Crystal Palace (h) Sat Aug 23 – West Ham United (a) Sat Aug 30 – Fulham (h) Sat Sep 13 – Brentford (a) Sat Sep 20 – Manchester United (a) Sat Sep 27 – Brighton & Hove Albion (h) Sat Oct 4 – Liverpool (h) Sat Oct 18 – Nottingham Forest (a) Sat Oct 25 – Sunderland (h) Sat Nov 1 – Tottenham Hotspur (a) Sat Nov 8 – Wolverhampton Wanderers (h) Sat Nov 22 – Burnley (a) Sat Nov 29 – Arsenal (h) Wed Dec 3 – Leeds United (a) Sat Dec 6 – A.F.C. Bournemouth (a) Sat Dec 13 – Everton (h) Sat Dec 20 – Newcastle United (a) Sat Dec 27 – Aston Villa (h) Tue Dec 30 – A.F.C. Bournemouth (h) Sat Jan 3 – Manchester City (a) Wed Jan 7 – Fulham (a) Sat Jan 17 – Brentford (h) Sat Jan 24 – Crystal Palace (a) Sat Jan 31 – West Ham United (h) Sat Feb 7 – Wolverhampton Wanderers (a) Wed Feb 11 – Leeds United (h) Sat Feb 21 – Burnley (h) Sat Feb 28 – Arsenal (a) Wed Mar 4 – Aston Villa (a) Sat Mar 14 – Newcastle United (h) Sat Mar 21 – Everton (a) Sat Apr 11 – Manchester City (h) Sat Apr 18 – Manchester United (h) Sat Apr 25 – Brighton & Hove Albion (a) Sat May 2 – Nottingham Forest (h) Sat May 9 – Liverpool (a) Sun May 17 – Tottenham Hotspur (h) Sun May 24 – Sunderland (a) 'It might not seem that way but having four London derbies will take it out of them. Those games will be fierce and there will be a lot of pressure from both sets of fans. 'Crystal Palace, West Ham, Fulham and Brentford will all be desperate to beat them, they would've been better off having some games with less pressure on to start the season. 'Pressure will be on the players because they are must-win games, it will not be easy for Enzo Maresca.' MORE: Cole Palmer makes surprise admission as he explains shirt number change MORE: Arsenal urged to sign 'unfairly treated' £40m Man City star MORE: West Ham approached by Juventus over £30m swap deal

The Independent

20 minutes ago

• The Independent

US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need

US medicines regulator the Food and Drug Administration (FDA) has approved a groundbreaking HIV prevention jab hailed as having the potential to quell the Aids pandemic. But the moment has been overshadowed by the spectre of aid cuts, placing in doubt whether this breakthrough injection – lenacapavir – will get to the people who need it most. Lenacapavir given in a twice-yearly injection stops HIV from replicating, protecting close to 100 per cent of people from developing the virus if they are exposed to it. This approval is one of the last crucial steps to getting the drug, branded Yeztugo, out to patients. Although the FDA's approval only applies to US patients, the World Health Organization (WHO) said it paved the way for its own recommendation of the drug and for approval in other countries. Director of WHO's Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty described it as a 'regulatory milestone' adding: 'We are working with partners and national authorities to ensure lenacapavir reaches people who need it most – quickly, safely and equitably.' Researchers have raised concerns that, amid aid cuts, the jab will be too expensive to be taken up by lower-income countries. Gilead – the drugs company producing lencapavir – did not make public the cost of each dose to global funders but it announced a US price of $28,218 per year for each patient. 'If this game-changing medicine remains unaffordable, it will change nothing,' said Winnie Byanyima, executive director of the United Nations' Aids agency, UNAIDS. She called the approval of lenacapavir a 'breakthrough moment' adding the jab, 'could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit. ' UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218.' Dr Andrew Hill, a pharmacology research fellow at the University of Liverpool, worked on the research which found lenacapavir could be provided for as little as $25, including a 30 per cent profit margin. 'Scientifically, it's a great moment that we have a drug which has been judged to be safe and efficacious by a leading regulatory authority in the world,'' he said. 'Public health-wise and in terms of the epidemic, it's tragic because the drug is so expensive that it's not going to get used'. It is also unlikely to be affordable in the UK, he said, despite government promises to end new cases of HIV in England by 2030. A Gilead spokesperson said, 'Yeztugo is priced in line with existing branded PrEP [pre-exposure prophylaxis] options. We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage in the US. 'We're taking unprecedented actions with urgency to plan for access to lenacapavir for PrEP globally—particularly in low- and lower-middle-income countries where the need is greatest.' Gilead signed agreements with six pharmaceutical companies in India, Pakistan, Egypt, and the US to allow them to make generic versions of the drug in order to increase supply and drive down the cost of the jab. This will take some time. Gilead also agreed to sell enough doses of the jab to protect at least two million people over three years in lower-income countries. These would be paid for by global funders led by the US President's Emergency Plan for Aids Relief (Pepfar) and the Global Fund to Fight Aids, Tuberculosis and Malaria. However, The Independent reported earlier in the month that these doses are now at risk because of US funding cuts. A significant chunk of the money to fund the doses of lenacapavir was set to come from the US-led global Aids response programme, Pepfar, as well as the Global Fund whose biggest donor was the US. This funding is now uncertain. Figures previously reported by The Independent suggest President Trump's slashing of foreign aid has derailed the projected end of the Aids pandemic and could lead to four million extra deaths by 2030. 'It does feel like this thing that could help us end the epidemic sooner is suddenly receding in the chaos,' said Prof Linda-Gail Bekker, whose trial demonstrated lenacapavir's effectiveness. The aid-funded doses are thought to cost much less than the US list price of almost $30k but still roughly five times more expensive than Dr Hill believes is necessary. And they are in an initial pilot phase, he said: 'We need to get into a different level where we're giving lenacapavir to tens of millions of people'. This is even more important as aid cuts are slashing the HIV prevention budgets of governments across Africa, he said. 'We're in this crazy position where we have a brand new highly effective vaccine-like drug and actually we will probably see the epidemic get worse over the next four years.'